GX1 Stock Overview
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Marker Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.93 |
| 52 Week High | US$5.30 |
| 52 Week Low | US$0.76 |
| Beta | 1.3 |
| 1 Month Change | 15.63% |
| 3 Month Change | -37.50% |
| 1 Year Change | -76.52% |
| 3 Year Change | n/a |
| 5 Year Change | -96.27% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| GX1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.6% | -0.6% | 0.8% |
| 1Y | -76.5% | -12.3% | 14.6% |
Return vs Industry: GX1 underperformed the German Biotechs industry which returned -12.3% over the past year.
Return vs Market: GX1 underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| GX1 volatility | |
|---|---|
| GX1 Average Weekly Movement | 25.3% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: GX1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: GX1's weekly volatility has increased from 19% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 5 | Juan Vera | markertherapeutics.com |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer.
Marker Therapeutics, Inc. Fundamentals Summary
| GX1 fundamental statistics | |
|---|---|
| Market cap | €10.66m |
| Earnings (TTM) | -€11.47m |
| Revenue (TTM) | €5.11m |
2.1x
P/S Ratio-0.9x
P/E RatioIs GX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GX1 income statement (TTM) | |
|---|---|
| Revenue | US$5.70m |
| Cost of Revenue | US$13.47m |
| Gross Profit | -US$7.77m |
| Other Expenses | US$5.01m |
| Earnings | -US$12.78m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19 |
| Gross Margin | -136.44% |
| Net Profit Margin | -224.45% |
| Debt/Equity Ratio | 0% |
How did GX1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/17 08:26 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marker Therapeutics, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| John Newman | Canaccord Genuity |
| Yun Zhong | Janney Montgomery Scott LLC |